APO Research
Talk to an analyst

APO RESEARCH · REPORT

Oral Hypoglycemic Agents

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Oral Hypoglycemic Agents Market Outlook and Growth Opportunities 2026

31 December 2025193 pages

Choose your research edition.

Industry ResearchOral Hypoglycemic Agents Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Oral Hypoglycemic Agents Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Oral Hypoglycemic Agents Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oral Hypoglycemic Agents Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Oral Hypoglycemic Agents Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Oral Hypoglycemic Agents market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Oral Hypoglycemic Agents is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Oral Hypoglycemic Agents is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Oral Hypoglycemic Agents is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Oral Hypoglycemic Agents market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Oral Hypoglycemic Agents market include Janssen Pharmaceuticals, Abbott Laboratories, Takeda, Sanofi S.A., Novartis International AG, Merk and Co., Eli Lilly and Company, Pfizer Inc and Beohringer Ingelgeim, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Oral Hypoglycemic Agents market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Oral Hypoglycemic Agents and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Oral Hypoglycemic Agents revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Oral Hypoglycemic Agents market.

Oral Hypoglycemic Agents Segment by Company

Janssen Pharmaceuticals

Abbott Laboratories

Takeda

Sanofi S.A.

Novartis International AG

Merk and Co.

Eli Lilly and Company

Pfizer Inc

Beohringer Ingelgeim

Bristol Myers Squibb

Biocon Limited

Astellas Pharma Inc.

AstraZeneca plc

Oral Hypoglycemic Agents Segment by Type

Capsule

Tablet

Liquid

Oral Hypoglycemic Agents Segment by Application

Retail Pharmacies

Online Pharmacies

Hospital Pharmacies

Oral Hypoglycemic Agents Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Oral Hypoglycemic Agents status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Oral Hypoglycemic Agents key companies, revenue, market share, and recent developments.

3. To split the Oral Hypoglycemic Agents breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Oral Hypoglycemic Agents market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Oral Hypoglycemic Agents significant trends, drivers, influence factors in global and regions.

6. To analyze Oral Hypoglycemic Agents competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oral Hypoglycemic Agents market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oral Hypoglycemic Agents and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oral Hypoglycemic Agents.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Oral Hypoglycemic Agents industry.

Chapter 3: Detailed analysis of Oral Hypoglycemic Agents company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Oral Hypoglycemic Agents in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Oral Hypoglycemic Agents in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Oral Hypoglycemic Agents Industry Trends Table 2. Oral Hypoglycemic Agents Industry Drivers Table 3. Oral Hypoglycemic Agents Industry Opportunities and Challenges Table 4. Oral Hypoglycemic Agents Industry Restraints Table 5. Global Oral Hypoglycemic Agents Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Oral Hypoglycemic Agents Revenue Share by Company (2021-2026) Table 7. Global Oral Hypoglycemic Agents Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Oral Hypoglycemic Agents Key Company Manufacturing Base & Headquarters Table 9. Global Oral Hypoglycemic Agents Company, Product Type & Application Table 10. Global Oral Hypoglycemic Agents Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Oral Hypoglycemic Agents by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Capsule Table 15. Significant Companies of Tablet Table 16. Significant Companies of Liquid Table 17. Global Oral Hypoglycemic Agents Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Oral Hypoglycemic Agents Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Oral Hypoglycemic Agents Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Oral Hypoglycemic Agents Sales Value Share by Type (2021-2026) Table 21. Global Oral Hypoglycemic Agents Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Retail Pharmacies Table 23. Significant Companies of Online Pharmacies Table 24. Significant Companies of Hospital Pharmacies Table 25. Global Oral Hypoglycemic Agents Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Oral Hypoglycemic Agents Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Oral Hypoglycemic Agents Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Oral Hypoglycemic Agents Sales Value Share by Application (2021-2026) Table 29. Global Oral Hypoglycemic Agents Sales Value Share by Application (2027-2032) Table 30. Global Oral Hypoglycemic Agents Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Oral Hypoglycemic Agents Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Oral Hypoglycemic Agents Sales Value Share by Region (2021-2026) Table 33. Global Oral Hypoglycemic Agents Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Oral Hypoglycemic Agents Sales Value Share by Region (2027-2032) Table 35. Global Oral Hypoglycemic Agents Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Oral Hypoglycemic Agents Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Oral Hypoglycemic Agents Sales Value Market Share by Country (2021-2026) Table 38. Global Oral Hypoglycemic Agents Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Oral Hypoglycemic Agents Sales Value Market Share by Country (2027-2032) Table 40. Janssen Pharmaceuticals Company Information Table 41. Janssen Pharmaceuticals Business Overview Table 42. Janssen Pharmaceuticals Oral Hypoglycemic Agents Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Janssen Pharmaceuticals Oral Hypoglycemic Agents Product Portfolio Table 44. Janssen Pharmaceuticals Recent Development Table 45. Abbott Laboratories Company Information Table 46. Abbott Laboratories Business Overview Table 47. Abbott Laboratories Oral Hypoglycemic Agents Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Abbott Laboratories Oral Hypoglycemic Agents Product Portfolio Table 49. Abbott Laboratories Recent Development Table 50. Takeda Company Information Table 51. Takeda Business Overview Table 52. Takeda Oral Hypoglycemic Agents Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Takeda Oral Hypoglycemic Agents Product Portfolio Table 54. Takeda Recent Development Table 55. Sanofi S.A. Company Information Table 56. Sanofi S.A. Business Overview Table 57. Sanofi S.A. Oral Hypoglycemic Agents Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Sanofi S.A. Oral Hypoglycemic Agents Product Portfolio Table 59. Sanofi S.A. Recent Development Table 60. Novartis International AG Company Information Table 61. Novartis International AG Business Overview Table 62. Novartis International AG Oral Hypoglycemic Agents Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Novartis International AG Oral Hypoglycemic Agents Product Portfolio Table 64. Novartis International AG Recent Development Table 65. Merk and Co. Company Information Table 66. Merk and Co. Business Overview Table 67. Merk and Co. Oral Hypoglycemic Agents Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Merk and Co. Oral Hypoglycemic Agents Product Portfolio Table 69. Merk and Co. Recent Development Table 70. Eli Lilly and Company Company Information Table 71. Eli Lilly and Company Business Overview Table 72. Eli Lilly and Company Oral Hypoglycemic Agents Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Eli Lilly and Company Oral Hypoglycemic Agents Product Portfolio Table 74. Eli Lilly and Company Recent Development Table 75. Pfizer Inc Company Information Table 76. Pfizer Inc Business Overview Table 77. Pfizer Inc Oral Hypoglycemic Agents Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Pfizer Inc Oral Hypoglycemic Agents Product Portfolio Table 79. Pfizer Inc Recent Development Table 80. Beohringer Ingelgeim Company Information Table 81. Beohringer Ingelgeim Business Overview Table 82. Beohringer Ingelgeim Oral Hypoglycemic Agents Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Beohringer Ingelgeim Oral Hypoglycemic Agents Product Portfolio Table 84. Beohringer Ingelgeim Recent Development Table 85. Bristol Myers Squibb Company Information Table 86. Bristol Myers Squibb Business Overview Table 87. Bristol Myers Squibb Oral Hypoglycemic Agents Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Bristol Myers Squibb Oral Hypoglycemic Agents Product Portfolio Table 89. Bristol Myers Squibb Recent Development Table 90. Biocon Limited Company Information Table 91. Biocon Limited Business Overview Table 92. Biocon Limited Oral Hypoglycemic Agents Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Biocon Limited Oral Hypoglycemic Agents Product Portfolio Table 94. Biocon Limited Recent Development Table 95. Astellas Pharma Inc. Company Information Table 96. Astellas Pharma Inc. Business Overview Table 97. Astellas Pharma Inc. Oral Hypoglycemic Agents Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Astellas Pharma Inc. Oral Hypoglycemic Agents Product Portfolio Table 99. Astellas Pharma Inc. Recent Development Table 100. AstraZeneca plc Company Information Table 101. AstraZeneca plc Business Overview Table 102. AstraZeneca plc Oral Hypoglycemic Agents Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. AstraZeneca plc Oral Hypoglycemic Agents Product Portfolio Table 104. AstraZeneca plc Recent Development Table 105. Research Programs/Design for This Report Table 106. Authors List of This Report Table 107. Secondary Sources Table 108. Primary Sources List of Figures Figure 1. Oral Hypoglycemic Agents Product Image Figure 2. Global Oral Hypoglycemic Agents Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oral Hypoglycemic Agents Market Size (2021-2032) & (US$ Million) Figure 4. Global Oral Hypoglycemic Agents Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Capsule Image Figure 8. Tablet Image Figure 9. Liquid Image Figure 10. Global Oral Hypoglycemic Agents Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Oral Hypoglycemic Agents Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Oral Hypoglycemic Agents Sales Value Share by Type (2021-2032) Figure 13. Retail Pharmacies Image Figure 14. Online Pharmacies Image Figure 15. Hospital Pharmacies Image Figure 16. Global Oral Hypoglycemic Agents Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Oral Hypoglycemic Agents Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Oral Hypoglycemic Agents Sales Value Share by Application (2021-2032) Figure 19. Global Oral Hypoglycemic Agents Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Oral Hypoglycemic Agents Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Oral Hypoglycemic Agents Sales Value (2021-2032) & (US$ Million) Figure 22. North America Oral Hypoglycemic Agents Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Oral Hypoglycemic Agents Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Oral Hypoglycemic Agents Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Oral Hypoglycemic Agents Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Oral Hypoglycemic Agents Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Oral Hypoglycemic Agents Sales Value (2021-2032) & (US$ Million) Figure 28. South America Oral Hypoglycemic Agents Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Oral Hypoglycemic Agents Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Oral Hypoglycemic Agents Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Oral Hypoglycemic Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Oral Hypoglycemic Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Oral Hypoglycemic Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Oral Hypoglycemic Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Oral Hypoglycemic Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Oral Hypoglycemic Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Oral Hypoglycemic Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Oral Hypoglycemic Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Oral Hypoglycemic Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Oral Hypoglycemic Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Oral Hypoglycemic Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Oral Hypoglycemic Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Oral Hypoglycemic Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Oral Hypoglycemic Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Oral Hypoglycemic Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Oral Hypoglycemic Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Oral Hypoglycemic Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Oral Hypoglycemic Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Oral Hypoglycemic Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Oral Hypoglycemic Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Oral Hypoglycemic Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Oral Hypoglycemic Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Oral Hypoglycemic Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Oral Hypoglycemic Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Oral Hypoglycemic Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Oral Hypoglycemic Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Oral Hypoglycemic Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Oral Hypoglycemic Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Oral Hypoglycemic Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Oral Hypoglycemic Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Oral Hypoglycemic Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Oral Hypoglycemic Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Oral Hypoglycemic Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Oral Hypoglycemic Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Oral Hypoglycemic Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Oral Hypoglycemic Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Oral Hypoglycemic Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Oral Hypoglycemic Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Oral Hypoglycemic Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Oral Hypoglycemic Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Oral Hypoglycemic Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Oral Hypoglycemic Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Oral Hypoglycemic Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Oral Hypoglycemic Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Oral Hypoglycemic Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Oral Hypoglycemic Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Oral Hypoglycemic Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Oral Hypoglycemic Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Oral Hypoglycemic Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Oral Hypoglycemic Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Oral Hypoglycemic Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Oral Hypoglycemic Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Oral Hypoglycemic Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Oral Hypoglycemic Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Oral Hypoglycemic Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Oral Hypoglycemic Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Oral Hypoglycemic Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Oral Hypoglycemic Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Oral Hypoglycemic Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Oral Hypoglycemic Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Oral Hypoglycemic Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Oral Hypoglycemic Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Oral Hypoglycemic Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Oral Hypoglycemic Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Oral Hypoglycemic Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Oral Hypoglycemic Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Oral Hypoglycemic Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Oral Hypoglycemic Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Oral Hypoglycemic Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Oral Hypoglycemic Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Oral Hypoglycemic Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Oral Hypoglycemic Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Oral Hypoglycemic Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Oral Hypoglycemic Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Oral Hypoglycemic Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Oral Hypoglycemic Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Oral Hypoglycemic Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Oral Hypoglycemic Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Oral Hypoglycemic Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Oral Hypoglycemic Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Oral Hypoglycemic Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Oral Hypoglycemic Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Oral Hypoglycemic Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Oral Hypoglycemic Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Capsule
  • Tablet
  • Liquid
Applications
  • Retail Pharmacies
  • Online Pharmacies
  • Hospital Pharmacies
Companies covered
  • Janssen Pharmaceuticals
  • Abbott Laboratories
  • Takeda
  • Sanofi S.A.
  • Novartis International AG
  • Merk and Co.
  • Eli Lilly and Company
  • Pfizer Inc
  • Beohringer Ingelgeim
  • Bristol Myers Squibb
  • Biocon Limited
  • Astellas Pharma Inc.
  • AstraZeneca plc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Oral Hypoglycemic Agents Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Oral Hypoglycemic Agents Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Oral Hypoglycemic Agents Market Dynamics
  1. 2.1 Oral Hypoglycemic Agents Industry Trends
  2. 2.2 Oral Hypoglycemic Agents Industry Drivers
  3. 2.3 Oral Hypoglycemic Agents Industry Opportunities and Challenges
  4. 2.4 Oral Hypoglycemic Agents Industry Restraints
3 Oral Hypoglycemic Agents Market by Company
  1. 3.1 Global Oral Hypoglycemic Agents Company Revenue Ranking in 2025
  2. 3.2 Global Oral Hypoglycemic Agents Revenue by Company (2021-2026)
  3. 3.3 Global Oral Hypoglycemic Agents Company Ranking (2024-2026)
  4. 3.4 Global Oral Hypoglycemic Agents Company Manufacturing Base and Headquarters
  5. 3.5 Global Oral Hypoglycemic Agents Company Product Type and Application
  6. 3.6 Global Oral Hypoglycemic Agents Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Oral Hypoglycemic Agents Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Oral Hypoglycemic Agents Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Oral Hypoglycemic Agents Market by Type
  1. 4.1 Oral Hypoglycemic Agents Type Introduction
  2. 4.1.1 Capsule
  3. 4.1.2 Tablet
  4. 4.1.3 Liquid
  5. 4.2 Global Oral Hypoglycemic Agents Sales Value by Type
  6. 4.2.1 Global Oral Hypoglycemic Agents Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Oral Hypoglycemic Agents Sales Value by Type (2021-2032)
  8. 4.2.3 Global Oral Hypoglycemic Agents Sales Value Share by Type (2021-2032)
5 Oral Hypoglycemic Agents Market by Application
  1. 5.1 Oral Hypoglycemic Agents Application Introduction
  2. 5.1.1 Retail Pharmacies
  3. 5.1.2 Online Pharmacies
  4. 5.1.3 Hospital Pharmacies
  5. 5.2 Global Oral Hypoglycemic Agents Sales Value by Application
  6. 5.2.1 Global Oral Hypoglycemic Agents Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Oral Hypoglycemic Agents Sales Value by Application (2021-2032)
  8. 5.2.3 Global Oral Hypoglycemic Agents Sales Value Share by Application (2021-2032)
6 Oral Hypoglycemic Agents Regional Value Analysis
  1. 6.1 Global Oral Hypoglycemic Agents Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Oral Hypoglycemic Agents Sales Value by Region (2021-2032)
  3. 6.2.1 Global Oral Hypoglycemic Agents Sales Value by Region: 2021-2026
  4. 6.2.2 Global Oral Hypoglycemic Agents Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Oral Hypoglycemic Agents Sales Value (2021-2032)
  7. 6.3.2 North America Oral Hypoglycemic Agents Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Oral Hypoglycemic Agents Sales Value (2021-2032)
  10. 6.4.2 Europe Oral Hypoglycemic Agents Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Oral Hypoglycemic Agents Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Oral Hypoglycemic Agents Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Oral Hypoglycemic Agents Sales Value (2021-2032)
  16. 6.6.2 South America Oral Hypoglycemic Agents Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Oral Hypoglycemic Agents Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Oral Hypoglycemic Agents Sales Value Share by Country, 2025 VS 2032
7 Oral Hypoglycemic Agents Country-level Value Analysis
  1. 7.1 Global Oral Hypoglycemic Agents Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Oral Hypoglycemic Agents Sales Value by Country (2021-2032)
  3. 7.2.1 Global Oral Hypoglycemic Agents Sales Value by Country (2021-2026)
  4. 7.2.2 Global Oral Hypoglycemic Agents Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Oral Hypoglycemic Agents Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Oral Hypoglycemic Agents Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Oral Hypoglycemic Agents Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Oral Hypoglycemic Agents Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Oral Hypoglycemic Agents Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Oral Hypoglycemic Agents Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Oral Hypoglycemic Agents Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Oral Hypoglycemic Agents Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Oral Hypoglycemic Agents Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Oral Hypoglycemic Agents Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Oral Hypoglycemic Agents Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Oral Hypoglycemic Agents Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Oral Hypoglycemic Agents Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Oral Hypoglycemic Agents Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Oral Hypoglycemic Agents Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Oral Hypoglycemic Agents Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Oral Hypoglycemic Agents Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Oral Hypoglycemic Agents Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Oral Hypoglycemic Agents Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Oral Hypoglycemic Agents Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Oral Hypoglycemic Agents Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Oral Hypoglycemic Agents Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Oral Hypoglycemic Agents Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Oral Hypoglycemic Agents Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Oral Hypoglycemic Agents Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Oral Hypoglycemic Agents Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Oral Hypoglycemic Agents Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Oral Hypoglycemic Agents Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Oral Hypoglycemic Agents Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Oral Hypoglycemic Agents Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Oral Hypoglycemic Agents Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Oral Hypoglycemic Agents Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Oral Hypoglycemic Agents Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Oral Hypoglycemic Agents Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Oral Hypoglycemic Agents Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Oral Hypoglycemic Agents Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Oral Hypoglycemic Agents Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Oral Hypoglycemic Agents Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Oral Hypoglycemic Agents Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Oral Hypoglycemic Agents Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Oral Hypoglycemic Agents Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Oral Hypoglycemic Agents Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Oral Hypoglycemic Agents Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Oral Hypoglycemic Agents Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Oral Hypoglycemic Agents Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Oral Hypoglycemic Agents Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Oral Hypoglycemic Agents Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Oral Hypoglycemic Agents Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Oral Hypoglycemic Agents Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Oral Hypoglycemic Agents Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Oral Hypoglycemic Agents Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Oral Hypoglycemic Agents Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Oral Hypoglycemic Agents Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Oral Hypoglycemic Agents Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Oral Hypoglycemic Agents Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Oral Hypoglycemic Agents Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Oral Hypoglycemic Agents Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Oral Hypoglycemic Agents Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Oral Hypoglycemic Agents Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Oral Hypoglycemic Agents Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Oral Hypoglycemic Agents Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Oral Hypoglycemic Agents Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Oral Hypoglycemic Agents Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Oral Hypoglycemic Agents Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Oral Hypoglycemic Agents Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Oral Hypoglycemic Agents Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Oral Hypoglycemic Agents Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Oral Hypoglycemic Agents Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Oral Hypoglycemic Agents Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Oral Hypoglycemic Agents Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Oral Hypoglycemic Agents Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Oral Hypoglycemic Agents Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Oral Hypoglycemic Agents Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Oral Hypoglycemic Agents Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Oral Hypoglycemic Agents Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Oral Hypoglycemic Agents Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Oral Hypoglycemic Agents Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Oral Hypoglycemic Agents Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Oral Hypoglycemic Agents Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Oral Hypoglycemic Agents Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Oral Hypoglycemic Agents Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Oral Hypoglycemic Agents Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Oral Hypoglycemic Agents Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Oral Hypoglycemic Agents Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Janssen Pharmaceuticals
  2. 8.1.1 Janssen Pharmaceuticals Company Information
  3. 8.1.2 Janssen Pharmaceuticals Business Overview
  4. 8.1.3 Janssen Pharmaceuticals Oral Hypoglycemic Agents Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Janssen Pharmaceuticals Oral Hypoglycemic Agents Product Portfolio
  6. 8.1.5 Janssen Pharmaceuticals Recent Developments
  7. 8.2 Abbott Laboratories
  8. 8.2.1 Abbott Laboratories Company Information
  9. 8.2.2 Abbott Laboratories Business Overview
  10. 8.2.3 Abbott Laboratories Oral Hypoglycemic Agents Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Abbott Laboratories Oral Hypoglycemic Agents Product Portfolio
  12. 8.2.5 Abbott Laboratories Recent Developments
  13. 8.3 Takeda
  14. 8.3.1 Takeda Company Information
  15. 8.3.2 Takeda Business Overview
  16. 8.3.3 Takeda Oral Hypoglycemic Agents Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Takeda Oral Hypoglycemic Agents Product Portfolio
  18. 8.3.5 Takeda Recent Developments
  19. 8.4 Sanofi S.A.
  20. 8.4.1 Sanofi S.A. Company Information
  21. 8.4.2 Sanofi S.A. Business Overview
  22. 8.4.3 Sanofi S.A. Oral Hypoglycemic Agents Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Sanofi S.A. Oral Hypoglycemic Agents Product Portfolio
  24. 8.4.5 Sanofi S.A. Recent Developments
  25. 8.5 Novartis International AG
  26. 8.5.1 Novartis International AG Company Information
  27. 8.5.2 Novartis International AG Business Overview
  28. 8.5.3 Novartis International AG Oral Hypoglycemic Agents Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Novartis International AG Oral Hypoglycemic Agents Product Portfolio
  30. 8.5.5 Novartis International AG Recent Developments
  31. 8.6 Merk and Co.
  32. 8.6.1 Merk and Co. Company Information
  33. 8.6.2 Merk and Co. Business Overview
  34. 8.6.3 Merk and Co. Oral Hypoglycemic Agents Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Merk and Co. Oral Hypoglycemic Agents Product Portfolio
  36. 8.6.5 Merk and Co. Recent Developments
  37. 8.7 Eli Lilly and Company
  38. 8.7.1 Eli Lilly and Company Company Information
  39. 8.7.2 Eli Lilly and Company Business Overview
  40. 8.7.3 Eli Lilly and Company Oral Hypoglycemic Agents Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Eli Lilly and Company Oral Hypoglycemic Agents Product Portfolio
  42. 8.7.5 Eli Lilly and Company Recent Developments
  43. 8.8 Pfizer Inc
  44. 8.8.1 Pfizer Inc Company Information
  45. 8.8.2 Pfizer Inc Business Overview
  46. 8.8.3 Pfizer Inc Oral Hypoglycemic Agents Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Pfizer Inc Oral Hypoglycemic Agents Product Portfolio
  48. 8.8.5 Pfizer Inc Recent Developments
  49. 8.9 Beohringer Ingelgeim
  50. 8.9.1 Beohringer Ingelgeim Company Information
  51. 8.9.2 Beohringer Ingelgeim Business Overview
  52. 8.9.3 Beohringer Ingelgeim Oral Hypoglycemic Agents Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Beohringer Ingelgeim Oral Hypoglycemic Agents Product Portfolio
  54. 8.9.5 Beohringer Ingelgeim Recent Developments
  55. 8.10 Bristol Myers Squibb
  56. 8.10.1 Bristol Myers Squibb Company Information
  57. 8.10.2 Bristol Myers Squibb Business Overview
  58. 8.10.3 Bristol Myers Squibb Oral Hypoglycemic Agents Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Bristol Myers Squibb Oral Hypoglycemic Agents Product Portfolio
  60. 8.10.5 Bristol Myers Squibb Recent Developments
  61. 8.11 Biocon Limited
  62. 8.11.1 Biocon Limited Company Information
  63. 8.11.2 Biocon Limited Business Overview
  64. 8.11.3 Biocon Limited Oral Hypoglycemic Agents Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Biocon Limited Oral Hypoglycemic Agents Product Portfolio
  66. 8.11.5 Biocon Limited Recent Developments
  67. 8.12 Astellas Pharma Inc.
  68. 8.12.1 Astellas Pharma Inc. Company Information
  69. 8.12.2 Astellas Pharma Inc. Business Overview
  70. 8.12.3 Astellas Pharma Inc. Oral Hypoglycemic Agents Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Astellas Pharma Inc. Oral Hypoglycemic Agents Product Portfolio
  72. 8.12.5 Astellas Pharma Inc. Recent Developments
  73. 8.13 AstraZeneca plc
  74. 8.13.1 AstraZeneca plc Company Information
  75. 8.13.2 AstraZeneca plc Business Overview
  76. 8.13.3 AstraZeneca plc Oral Hypoglycemic Agents Revenue and Gross Margin (2021-2026)
  77. 8.13.4 AstraZeneca plc Oral Hypoglycemic Agents Product Portfolio
  78. 8.13.5 AstraZeneca plc Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst